Suzanne Bruhn, PhD

President and Chief Executive Officer

Suzanne Bruhn is the president and chief executive officer of Proclara. Previously, she served as president and chief executive officer of Promedior, a private, clinical-stage biotechnology company pioneering the development of targeted therapies to treat diseases involving fibrosis. At Promedior, Bruhn oversaw the development of PRM-151, a recombinant human pentraxin-2 protein,, and negotiated an agreement with Bristol-Myers Squibb, granting them the exclusive right to acquire Promedior and gain worldwide rights to its lead compound. Prior to Promedior, she served as senior vice president, strategic planning and program management for Shire Human Genetic Therapies, Inc., where she played a key role in developing multiple protein therapeutics for orphan diseases and in driving product strategy, portfolio and program management, and global regulatory affairs for the company’s rare disease portfolio. She also worked at Cytotherapeutics, Inc. Bruhn currently serves on the Board of Directors of Aeglea BioTherapeutics (NASDAQ: AGLE) and Pliant Therapeutics, and formerly served on the Board of Directors of Raptor Pharmaceuticals (NASDAQ: RPTP), prior to its 2016 acquisition by Horizon Pharma. She received a Bachelor of Science from Iowa State University, a doctorate in Chemistry from the Massachusetts Institute of Technology, and completed her postdoctoral fellowship in the department of human genetics at Harvard Medical School.